Literature DB >> 2187928

Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children.

L Smith1, A M Will, R F Williams, R F Stevens.   

Abstract

Efficacy of the cephalosporin, ceftriaxone, was compared with that of the combination of the aminoglycoside, netilmicin, and the penicillin, azlocillin, in the treatment of febrile episodes in immunocompromised neutropenic children undergoing chemotherapy for neoplastic disease. During 100 separate febrile episodes, 40 strains of bacteria were isolated from the blood of 34 patients and a further 55 strains from other sites. Nine strains (four of which were staphylococci) to both netilmicin and azlocillin. There was no difference in clinical response between the two therapeutic regimens as assessed 4 and 7 days after treatment began. Ceftriaxone had the considerable practical advantages of once daily dosage without a need for blood monitoring. Ceftriaxone would appear to be effective as initial monotherapy in the treatment of bacterial infections in severely neutropenic children.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187928     DOI: 10.1016/0163-4453(90)91019-a

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  5 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 2.  A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia.

Authors:  Arif Manji; Thomas Lehrnbecher; L Lee Dupuis; Joseph Beyene; Lillian Sung
Journal:  Support Care Cancer       Date:  2011-12-06       Impact factor: 3.603

3.  Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.

Authors:  R J Tomlinson; M Ronghe; C Goodbourne; C Price; J S Lilleyman; S Das; V Saha
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

Review 4.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 5.  Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Authors:  Mical Paul; Yaakov Dickstein; Agata Schlesinger; Simona Grozinsky-Glasberg; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.